You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 25, 2024

Details for Patent: 8,173,663


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,173,663
Title:Dipeptidyl peptidase inhibitors
Abstract: Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a compound comprising: ##STR00001## wherein M is N or CR.sub.4; Q.sup.1 and Q.sup.2 are each independently selected from the group consisting of CO, SO, SO.sub.2, and C.dbd.NR.sub.9; and each L, X, R.sub.1, R.sub.2, and R.sub.3 are as defined herein.
Inventor(s): Feng; Jun (Carlsbad, CA), Gwaltney; Stephen L. (San Diego, CA), Stafford; Jeffrey A. (San Diego, CA), Zhang; Zhiyuan (San Diego, CA), Elder; Bruce J. (Wynantskill, NY), Isbester; Paul K. (Castleton, NY), Palmer; Grant J. (Clifton Park, NY), Salsbury; Jonathon S. (Albany, NY), Ulysse; Luckner G. (Albany, NY)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:11/929,593
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,173,663
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

Detailed Analysis of the Scope and Claims of United States Patent 8,173,663

Introduction

United States Patent 8,173,663, titled "Dipeptidyl peptidase inhibitors," is a patent that has significant implications in the pharmaceutical industry, particularly in the development of treatments for diabetes and other metabolic disorders. This analysis will delve into the scope and claims of this patent, as well as the broader patent landscape surrounding dipeptidyl peptidase (DPP) inhibitors.

Patent Overview

Publication Details

  • Patent Number: US8173663B2
  • Publication Date: February 8, 2011
  • Assignee: Takeda Pharmaceutical Company Limited
  • Inventors: Various inventors associated with Takeda Pharmaceutical Company Limited[4].

Scope and Claims

Claim Structure

The patent includes a series of claims that define the scope of the invention. These claims are categorized into independent and dependent claims.

  • Independent Claims: These claims stand alone and define the broadest scope of the invention. For example, Claim 1 describes a compound of a specific chemical structure, which is a dipeptidyl peptidase inhibitor[4].
  • Dependent Claims: These claims are narrower and depend on the independent claims. They provide additional details or specific embodiments of the invention.

Claim Metrics

Research has shown that the length and count of independent claims can be indicative of the patent's scope. A study suggests that narrower claims at publication are associated with a higher probability of grant and a shorter examination process[3].

Claim Language

The claims in US8173663B2 are detailed and specific, outlining the chemical structures and properties of the dipeptidyl peptidase inhibitors. For instance, the claims describe compounds with particular phenyl, alkyl, and amino group configurations[4].

Patent Landscape Analysis

Technological Domain

Patent landscape analysis is crucial for understanding the technological domain of DPP inhibitors. This analysis involves mapping patents to identify key players, trends, and potential risks.

  • Competitors: Companies like Merck, Novartis, and Eli Lilly are also active in the DPP inhibitor space, with their own patents and developments[5].
  • Market Developments: The landscape includes information on mergers and acquisitions, licensing agreements, and litigation activities. For example, Takeda's strategic partnerships and licensing agreements can be identified through patent landscape reports[5].

Legal Status and Expiry Dates

Understanding the legal status and expected expiry dates of patents is vital for strategic planning.

  • Legal Status: The patent US8173663B2 is currently active but will expire based on its legal status and term extension, if any[4].
  • Expected Expiry Dates: Knowing the expiry dates helps in planning for generic competition or potential licensing opportunities[5].

Global Patent Family

The Global Dossier service provided by the USPTO allows users to view the patent family for a specific application, including related applications filed at participating IP Offices. This can help in understanding the global reach and protection of the invention[1].

International Patent Search

To ensure the novelty and non-obviousness of the invention, it is essential to conduct an international patent search.

  • European Patent Office (EPO): Using databases like esp@cenet, one can search for similar patents in Europe[1].
  • Japan Patent Office (JPO): Machine translations of Japanese patents can be accessed to identify any prior art in Japan[1].
  • World Intellectual Property Organization (WIPO): The PATENTSCOPE® Search Service provides a full-text search of published international patent applications, which can be useful for global patent searches[1].

Search Tools and Resources

Several tools and resources are available for conducting a comprehensive patent search:

  • Patent Public Search: This tool provides enhanced access to prior art and is a powerful resource for searching U.S. patents[1].
  • Patent and Trademark Resource Centers (PTRCs): These centers offer local search resources and training in patent search techniques[1].
  • Common Citation Document (CCD): This application consolidates citation data from participating IP Offices, helping to visualize search results on a single page[1].

Key Takeaways

  • Patent Scope: The scope of US8173663B2 is defined by its claims, which are specific and detailed, indicating a focused invention.
  • Patent Landscape: The landscape analysis reveals a competitive technological domain with multiple players, emphasizing the need for strategic planning and continuous monitoring.
  • Global Protection: Understanding the global patent family and legal status is crucial for managing intellectual property rights.
  • Search Tools: Utilizing advanced search tools and resources is essential for conducting thorough patent searches.

FAQs

What is the main subject of United States Patent 8,173,663?

The main subject of US8173663B2 is dipeptidyl peptidase inhibitors, which are compounds used in the treatment of diabetes and other metabolic disorders.

How can I determine the scope of a patent?

The scope of a patent is determined by its claims, which can be analyzed using metrics such as independent claim length and independent claim count.

What is patent landscape analysis, and why is it important?

Patent landscape analysis is a process that uses computer tools and human intelligence to analyze and organize patent data. It is important for understanding the technological domain, identifying competitors, and making strategic business decisions.

Where can I find information on the global patent family of a specific patent?

The Global Dossier service provided by the USPTO allows users to view the patent family for a specific application, including related applications filed at participating IP Offices.

What tools are available for conducting a comprehensive patent search?

Tools such as Patent Public Search, Patent and Trademark Resource Centers (PTRCs), and the Common Citation Document (CCD) application are available for conducting comprehensive patent searches.

Sources

  1. USPTO - Search for patents: https://www.uspto.gov/patents/search
  2. Regulations.gov - Patent Term Extension Application for NESINA®: https://www.regulations.gov/docket/FDA-2014-E-0154
  3. SSRN - Patent Claims and Patent Scope: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2844964
  4. Google Patents - US8173663B2 - Dipeptidyl peptidase inhibitors: https://patents.google.com/patent/US8173663B2/en
  5. Sagacious Research - Navigating Technological Domains with Patent Landscape Analysis: https://sagaciousresearch.com/blog/navigating-technological-domains-with-patent-landscape-analysis/

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 8,173,663

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Takeda Pharms Usa KAZANO alogliptin benzoate; metformin hydrochloride TABLET;ORAL 203414-002 Jan 25, 2013 RX Yes Yes 8,173,663 ⤷  Subscribe METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN ⤷  Subscribe
Takeda Pharms Usa KAZANO alogliptin benzoate; metformin hydrochloride TABLET;ORAL 203414-001 Jan 25, 2013 RX Yes No 8,173,663 ⤷  Subscribe METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN ⤷  Subscribe
Takeda Pharms Usa NESINA alogliptin benzoate TABLET;ORAL 022271-001 Jan 25, 2013 RX Yes No 8,173,663 ⤷  Subscribe METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN ⤷  Subscribe
Takeda Pharms Usa NESINA alogliptin benzoate TABLET;ORAL 022271-002 Jan 25, 2013 RX Yes No 8,173,663 ⤷  Subscribe METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,173,663

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1586571 ⤷  Subscribe C300640 Netherlands ⤷  Subscribe
European Patent Office 1586571 ⤷  Subscribe CA 2014 00011 Denmark ⤷  Subscribe
European Patent Office 1586571 ⤷  Subscribe PA2014011 Lithuania ⤷  Subscribe
European Patent Office 1586571 ⤷  Subscribe 14C0013 France ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.